Earnings NYSE Nasdaq 100 U.S. Tech Politics Science AI SEC Business Wall Street Energy Dow Jones Dividend Bitcoin (BTC) NVIDIA (NVDA) Markets Investing Economy S&P 500 China Donald Trump World Fed Crude Oil Tesla (TSLA) Money Inflation Gold Software U.K. Entertainment Apple (AAPL) Wealth Health Amazon (AMZN) Retail Taxes 3M (MMM) Real Estate Elon Musk Europe Natural Gas Microsoft (MSFT) Security Retirement Meta Platforms (META) Current Canada Truist Financial Corp (TFC) Options Boeing (BA) Jim Cramer Tax Hedge Funds Insurance Sports Google Live Manufacturing Economics Pharmaceuticals Cars Mining Costco (COST) Airlines War Warren Buffett Japan Ukraine Construction Silver York Interest Rates Holidays BlackRock (BLK) New York Finance Kamala Harris Goldman Sachs (GS) REITs Space Mortgage Internet Walmart (WMT) JPMorgan (JPM) Aerospace OpenAI ChatGPT Ethereum (ETH) Intel (INTC) Enterprise Walt Disney (DIS) GBP USD Netflix (NFLX) Australia Morgan Stanley (MS) India Boston IPOsMore +
Market Insider Market Insider
  • Stocks
  • ETFs
  • Bonds
  • Commodities
  • Earnings
  • Dividends
  • REITs
  • IPOs
  • Cryptocurrency
  • Forex
  • Tech
  • Politics
  • +

6 hours Biomarin: Challanges Mount, But Sale Rumours Make For A Risky “Buy” CallSeeking Alpha

Biomarin: Challanges Mount, But Sale Rumours Make For A Risky “Buy” Call.

Biomarin Pharma (BMRN)

X       

4 hours Why Is BioMarin Pharmaceutical Inc. (BMRN) Among the Worst Performing Biotech Stocks in 2024?Insider Monkey X       

11 hours Here’s Why BioMarin Pharmaceutical (BMRN) is a Strong Value StockZacks X       

1 day Here’s Why BioMarin Pharmaceutical (BMRN) is a Strong Growth StockZacks X       

2 weeks Here’s Why BioMarin Aristotle Large Cap Growth Strategy Divested From Pharmaceutical (BMRN)Insider Monkey X       

2 weeks Is BioMarin (BMRN) a Solid Growth Stock? 3 Reasons to Think “Yes”Zacks X       

2 weeks BioMarin (BMRN) Upgraded to Buy: Here’s WhyZacks X       

2 weeks BMRN vs. INCY: Which Stock Is the Better Value Option?Zacks X       

3 weeks Earnings call: BioMarin reports robust Q3 growth with VOXZOGO sales surgeInvesting.com X       

3 weeks Royal Bank of Canada Reiterates “Sector Perform” Rating for BioMarin Pharmaceutical (NASDAQ:BMRN)MarketBeat X       

3 weeks BioMarin Q3 Earnings & Revenues Beat Estimates, ’24 Guidance RaisedZacks X       

3 weeks BioMarin Pharmaceutical Inc. (BMRN) Q3 2024 Earnings Call TranscriptSeeking Alpha X       

3 weeks BioMarin (BMRN) Q3 Earnings: Taking a Look at Key Metrics Versus EstimatesZacks X       

1 month BioMarin Pharmaceutical (BMRN) to Release Quarterly Earnings on TuesdayMarketBeat X       

More news +
Home | Contact
  • X

© 2024 Market Insider